Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 59,574,628
  • Shares Outstanding, K 211,430
  • Annual Sales, $ 11,449 M
  • Annual Income, $ 3,703 M
  • 36-Month Beta 0.79
  • Price/Sales 5.25
  • Price/Cash Flow 12.03
  • Price/Book 5.20

Price Performance

See More
Period Period Low Period High Performance
1-Month
280.01 +0.63%
on 07/24/17
296.95 -5.11%
on 07/26/17
-0.83 (-0.29%)
since 07/18/17
3-Month
244.28 +15.35%
on 05/31/17
296.95 -5.11%
on 07/26/17
+28.96 (+11.46%)
since 05/18/17
52-Week
244.28 +15.35%
on 05/31/17
303.81 -7.25%
on 11/10/16
-6.89 (-2.39%)
since 08/18/16

Most Recent Stories

More News
Today's Research Reports on Stocks to Watch: Biogen Inc. and MannKind Corporation

NEW YORK, NY / ACCESSWIRE / August 17, 2017 / Biogen saw its market cap increase over $1 billion in Wednesday trading after Goldman Sachs took a big bet on the company by adding it to its "conviction buy"...

MNKD : 1.46 (+4.29%)
BIIB : 281.77 (-0.93%)
What You See, and What You Get: The Neurology of Perception

While "the biotech century" cures cancer, it's also tackling dozens of neurological diseases investors should learn about.

SGMO : 9.90 (-3.41%)
SRPT : 36.70 (-0.46%)
NBIX : 52.15 (-1.83%)
ACAD : 31.08 (+0.16%)
ALKS : 50.90 (-0.04%)
BIIB : 281.77 (-0.93%)
Biogen Inc Rises 1.20% on Heavy Volume: Watch For Potential Pullback

Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $285.51 to a high of $289.71. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $287.11...

BIIB : 281.77 (-0.93%)
After Yesterday's Rally of 1.20% Shares Could Potentially Pullback

Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $285.51 to a high of $289.71. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $287.11...

BIIB : 281.77 (-0.93%)
Watch for Biogen Inc to Potentially Rebound After Falling 2.35% Yesterday

Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $281.56 to a high of $287.11. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of $285.73...

BIIB : 281.77 (-0.93%)
AGTC Files Investigational New Drug Application for the Treatment of X-linked Retinitis Pigmentosa Caused by Mutations in the RPGR Gene

Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases,...

AGTC : 4.80 (-8.57%)
BIIB : 281.77 (-0.93%)
The Zacks Analyst Blog Highlights: Biogen, Activision, Cigna Kraft Heinz and Equinix

The Zacks Analyst Blog Highlights: Biogen, Activision, Cigna Kraft Heinz and Equinix

CI : 177.03 (-0.56%)
KHC : 84.49 (-0.73%)
ATVI : 62.01 (+1.04%)
EQIX : 450.00 (-0.34%)
BIIB : 281.77 (-0.93%)
Top Analyst Reports for Biogen, Activision & Cigna

Top Analyst Reports for Biogen, Activision & Cigna

CI : 177.03 (-0.56%)
KHC : 84.49 (-0.73%)
ATVI : 62.01 (+1.04%)
CTSH : 70.07 (-0.45%)
EQIX : 450.00 (-0.34%)
BIIB : 281.77 (-0.93%)
PDL BioPharma (PDLI) Q2 Earnings Beat, Revenues Rise Y/Y

PDL BioPharma's (PDLI) earnings surpass expectations. Revenues also significantly increase year over year, thanks to a rise in fair value of the Depomed royalty asset.

ENZ : 10.78 (-2.00%)
PDLI : 2.72 (-0.37%)
VRX : 14.39 (+0.35%)
BIIB : 281.77 (-0.93%)
Is a Beat in Store for Ionis (IONS) This Earnings Season?

Ionis Pharmaceuticals, Inc. (IONS) received marketing approval in the EU for spinal muscular atrophy and its launch is expected to further grow sales in Q2.

ESPR : 44.74 (-0.53%)
IONS : 46.98 (-0.36%)
TSRO : 113.86 (+4.41%)
BIIB : 281.77 (-0.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Support & Resistance

2nd Resistance Point 287.05
1st Resistance Point 284.41
Last Price 281.77
1st Support Level 280.39
2nd Support Level 279.01

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.